Effective 6/15/2026, Cigna consolidated and clarified coverage criteria for serum vitamin D testing in Medical Coverage Policy 0526, separating total 25(OH)D testing (CPT 82306/0038U) from active 1,25(OH)2D testing (CPT 82652) with distinct indications for each assay. Hepatobiliary and pancreatic conditions — including hepatic failure, advanced hepatic fibrosis, chronic pancreatitis, exocrine pancreatic insufficiency, cystic fibrosis, Crohn’s disease, celiac disease, and related malabsorption codes — are explicitly listed as medically necessary indications for total 25(OH)D testing. The policy maps these clinical indications to specific ICD code ranges (e.g., K72.x, K74.02, K86.x, K90.x, E84.x, K50.x) to operationalize coverage. Specialty society guidance (ACG, AGA) is cited to support testing in chronic pancreatitis, primary sclerosing cholangitis, celiac disease, and exocrine pancreatic insufficiency.
June 15, 2026 Revision: Consolidated Coverage Criteria for Vitamin D Testing
This revision (effective 6/15/2026) clarifies and consolidates coverage criteria for serum vitamin D testing within Cigna's Medical Coverage Policy 0526. The document explicitly lists indications for total serum vitamin D testing (Serum 25(OH)D, CPT 82306 or CPT 0038U) and separates indications for active serum vitamin D testing (Serum 1,25(OH)2D, CPT 82652). The effective date appears at the top of the policy and multiple sections reiterate coverage effective 6/15/2026 for diagnostic codes and guideline citations.
The update incorporates condition-specific language that calls out hepatobiliary and pancreatic conditions (e.g., hepatic failure, exocrine pancreatic insufficiency, chronic pancreatitis) as covered indications, and aligns these indications with ICD code ranges included in the same effective-date block. The policy also references specialty society guidance (ACG, AGA) to support testing in chronic pancreatitis, Crohn's disease, primary sclerosing cholangitis, celiac disease, and exocrine pancreatic insufficiency.
Covered Indications: Total Serum Vitamin D (`Serum 25(OH)D`)
The policy defines medically necessary coverage for total serum vitamin D testing (Serum 25(OH)D, CPT 82306 or CPT 0038U) when an individual has ANY of a specified list of conditions or risk factors. Key hepatobiliary and pancreatic indications explicitly listed include hepatic failure, exocrine pancreatic insufficiency, and chronic pancreatitis. Other listed indications include rickets, osteomalacia, osteoporosis, chronic kidney disease, malabsorption syndromes, hyperparathyroidism, certain medications, history of nontraumatic fractures, granulomatous disorders, lymphomas, genetic syndromes, age ≤ 18 years, age > 64 years, previously documented vitamin D deficiency, and known or suspected vitamin D toxicity.
The policy presents these as inclusive criteria — presence of any one listed condition or risk factor qualifies total serum vitamin D testing as medically necessary under this coverage statement.
Active Vitamin D Testing (`Serum 1,25(OH)2D`) Coverage Statement
Active serum vitamin D testing (Serum 1,25(OH)2D, CPT 82652) is addressed separately and is considered medically necessary for individuals meeting any of the policy's listed indications for that assay. While the excerpt provided does not reproduce the full enumerated list under the active test heading, the policy structure distinguishes the 1,25(OH)2D assay from the 25(OH)D assay and signals that different clinical scenarios may warrant the active form testing.
This separation reflects Cigna's explicit coding approach: CPT 82306/0038U are tied to 25(OH)D coverage criteria, whereas CPT 82652 coverage is governed by its own set of clinical indications within the same policy framework.
Diagnosis Coding Links to Hepatobiliary and Pancreatic Indications
The policy includes extensive ICD code ranges tied to the effective 6/15/2026 coverage block, linking clinical indications to specific diagnostic codes. Included codes relevant to hepatobiliary and pancreatic disease include K72.00-K72.91 (hepatic failure), K74.02 (advanced hepatic fibrosis), K86.0-K86.81 (other diseases of pancreas), and K90.x series for malabsorption conditions (e.g., K90.0 celiac disease). Additional codes cover cystic fibrosis (E84.0-E84.9), Crohn's disease (K50.00-K50.919), and postsurgical or postprocedural malabsorption and hepatic failure (K91.2, K91.82).
These code listings demonstrate the policy's intent to operationalize coverage decisions through diagnosis coding that maps to the enumerated clinical indications for vitamin D testing.
Guideline Support: ACG and AGA Recommendations for Testing in Liver and Pancreas Disease
The policy cites specialty society guidance to support coverage decisions for vitamin D testing in the context of liver and pancreatic disease. For example, the ACG Chronic Pancreatitis guideline (Gardner et al., 2020) is quoted stating that patients with chronic pancreatitis should undergo periodic evaluation for malnutrition, including testing for fat-soluble vitamin deficiencies. The ACG Primary Sclerosing Cholangitis guidance (Lindor et al., 2015) recommends assessing vitamins A, E, and D in patients with advanced liver disease. AGA updates are also referenced — including recommendations to evaluate fat-soluble vitamin status in celiac disease and baseline nutrient/vitamin measurements in exocrine pancreatic insufficiency (Whitcomb et al., 2023).
These guideline citations are incorporated in the policy narrative to justify inclusion of hepatobiliary and pancreatic conditions among the medically necessary indications for vitamin D testing.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.